Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning

References

• Centers for Disease Control and Prevention. National diabetes statistics report website; [cited 2022 Feb 3]. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html.
   Google Scholar
• American Diabetes Association Professional Practice Committee 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90–S102.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetologia. 2018;61(12):2461–2498.
   PubMed Web of Science ®Google Scholar
• Peng XV, McCrimmon RJ, Shepherd L, et al. Glycemic control following GLP-1 RA or basal insulin initiation in real-world practice: a retrospective, observational, longitudinal cohort study. Diabetes Ther. 2020;11(11):2629–2645.
   PubMed Web of Science ®Google Scholar
• Blonde L, Meneghini L, Peng XV, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in Real-World practice in the USA. Diabetes Ther. 2018;9(3):1347–1358.
   PubMed Web of Science ®Google Scholar
• Brixner D, Ermakova A, Xiong Y, et al. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: a retrospective cohort study. Clin Ther. 2019;41(2):303–313.e1.
   PubMed Web of Science ®Google Scholar
• Raccah D, Chou E, Colagiuri S, et al. A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin. Diabetes Metab Res Rev. 2017;33(3):e2858.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Chandran A, DiMario S, et al. Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study. BMJ Open Diabetes Res Care. 2016;4(1):e000189.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2015;39(Supplement 1):S52–S59.
   Google Scholar
• Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978;1(6107):204–207.
   PubMed Web of Science ®Google Scholar
• Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012;366(17):1616–1624.
   PubMed Web of Science ®Google Scholar
• Perez-Nieves M, Juneja R, Fan L, et al. Trends in U.S. Insulin use and glucose monitoring for people with diabetes: 2009–2018. J Diabetes Sci Technol. 2022;16(6):1428–1435.
   PubMedGoogle Scholar
• Basu S, Yudkin JS, Kehlenbrink S, et al. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(1):25–33.
   PubMed Web of Science ®Google Scholar
• Bode BW. Insulin pump use in type 2 diabetes. Diabetes Technol Ther. 2010;12 (Suppl 1)::S17–21.
   PubMed Web of Science ®Google Scholar
• National coverage determination (NCD) for infusion pumps. CMS website; [cited 2004 Dec 17]. Available from: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=223.
   Google Scholar
• Ackermann RT, Wallia A, Kang R, et al. Comparative effectiveness and costs of insulin pump therapy for diabetes. Am J Manag Care. 2017;23(6):353–359.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services: Infusion Pumps: C-Peptide Levels as a Criterion for Use. Medicare National Coverage Determinations; [cited 2005 Feb 4]. Available from: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/r27ncd.pdf.
   Google Scholar
• Lee LJ, Anderson J, Foster SA, et al. Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes. J Diabetes Sci Technol. 2010;4(3):547–557.
   PubMedGoogle Scholar
• Daly A, Hovorka R. Technology in the management of type 2 diabetes: present status and future prospects. Diabetes Obes Metab. 2021;23(8):1722–1732.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association 7. Diabetes technology: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S85–s99.
   PubMed Web of Science ®Google Scholar
• Berthe E, Lireux B, Coffin C, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res. 2007;39(3):224–229.
   PubMed Web of Science ®Google Scholar
• Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med. 2005;22(8):1037–1046.
   PubMed Web of Science ®Google Scholar
• Reznik Y, Cohen O, Aronson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet. 2014;384(9950):1265–1272.
   PubMed Web of Science ®Google Scholar
• Reznik Y, Morera J, Rod A, et al. Efficacy of continuous subcutaneous insulin infusion in type 2 diabetes mellitus: a survey on a cohort of 102 patients with prolonged follow-up. Diabetes Technol Ther. 2010;12(12):931–936.
   PubMed Web of Science ®Google Scholar
• Pickup JC, Reznik Y, Sutton AJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and meta-regression of randomized controlled trials. Diabetes Care. 2017;40(5):715–722.
   PubMed Web of Science ®Google Scholar
• Mader JK, Lilly LC, Aberer F, et al. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with type 2 diabetes. Diabet Med. 2018;35(10):1448–1456.
   PubMed Web of Science ®Google Scholar
• Layne JE, Parkin CG, Zisser H. Efficacy of a tubeless patch pump in patients with type 2 diabetes previously treated with multiple daily injections. J Diabetes Sci Technol. 2017;11(1):178–179.
   PubMedGoogle Scholar
• Grunberger G, Sze D, Ermakova A, et al. Treatment intensification with insulin pumps and other technologies in patients with type 2 diabetes: results of a physician survey in the United States. Clin Diabetes. 2020;38(1):47–55.
   PubMedGoogle Scholar
• Vigersky RA, Huang S, Cordero TL, et al. Improved HbA1c, total daily insulin dose, and treatment satisfaction with insulin pump therapy compared to multiple daily insulin injections in patients with type 2 diabetes irrespective of baseline C-peptide levels. Endocr Pract. 2018;24(5):446–452.
   PubMed Web of Science ®Google Scholar
• Schroeder EB, Donahoo WT, Goodrich GK, et al. Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data. Pharmacoepidemiol Drug Saf. 2018;27(10):1053–1059.
   PubMed Web of Science ®Google Scholar
• Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med. 2004;61(12):e59.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Glynn RJ, Wang S, et al. Performance of disease risk score matching in nested Case-Control studies: a simulation study. Am J Epidemiol. 2016;183(10):949–957.
   PubMed Web of Science ®Google Scholar
• Wicke FS, Glushan A, Schubert I, et al. Performance of the adapted diabetes complications severity index translated to ICD-10. Am J Manag Care. 2019;25(2):e45–e49.
   PubMed Web of Science ®Google Scholar
• R Core Team. 2021. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
   Google Scholar
• Hankosky E, Katz M, Fan L, et al. Characteristics of people with Type 2 diabetes initiating an insulin pump: data from a large commercial claims database - Poster presented at Advanced Technologies and Treatments for Diabetes, June 2-5, 2021 (Virtual). Diabetes Technology & Therapeutics; 2021. P190(#76).
   Google Scholar
• van Bon AC, Kohinor MJ, Hoekstra JB, et al. Patients’ perception and future acceptance of an artificial pancreas. J Diabetes Sci Technol. 2010;4(3):596–602.
   PubMedGoogle Scholar
• Borges U, Jr., Kubiak T. Continuous glucose monitoring in type 1 diabetes. J Diabetes Sci Technol. 2016;10(3):633–639.
   PubMedGoogle Scholar
• Tanenbaum ML, Adams RN, Hanes SJ, et al. Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use. J Diabetes Sci Technol. 2017;11(3):484–492.
   PubMedGoogle Scholar
• Association AD. Health equity and diabetes technology: a study of access to continuous glucose monitors by payer and race. Executive Summary; Arlington, VA; 2021.
   Google Scholar
• Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023;11(1):42–57.
   PubMed Web of Science ®Google Scholar
• Fu AZ, Sheehan JJ. Treatment intensification for patients with type 2 diabetes and poor glycaemic control. Diabetes Obes Metab. 2016;18(9):892–898.
   PubMed Web of Science ®Google Scholar
• Meunier L, Aguadé AS, Videau Y, et al. Age, male gender, and social deprivation are associated with a lower rate of insulin pump therapy initiation in adults with type 1 diabetes: a Population-Based study. Diabetes Technol Ther. 2021;23(1):8–19.
   PubMed Web of Science ®Google Scholar
• Stephens EA, Heffner J. Evaluating older patients with diabetes for insulin pump therapy. Diabetes Technol Ther. 2010;12(Suppl 1):S91–S7.
   PubMed Web of Science ®Google Scholar
• Kumareswaran K, Thabit H, Leelarathna L, et al. Feasibility of closed-loop insulin delivery in type 2 diabetes: a randomized controlled study. Diabetes Care. 2014;37(5):1198–1203.
   PubMed Web of Science ®Google Scholar
• Toschi E, Munshi MN. Benefits and challenges of diabetes technology use in older adults. Endocrinol Metab Clin North Am. 2020;49(1):57–67.
   PubMed Web of Science ®Google Scholar
• Burckhardt MA, Smith GJ, Cooper MN, et al. Real-world outcomes of insulin pump compared to injection therapy in a population-based sample of children with type 1 diabetes. Pediatr Diabetes. 2018;19(8):1459–1466.
   PubMed Web of Science ®Google Scholar
• Karter AJ, Moffet HH, Liu JY, et al. Surveillance of Hypoglycemia-Limitations of emergency department and hospital utilization data. JAMA Intern Med. 2018;178(7):987–988.
   PubMed Web of Science ®Google Scholar
• IBM. MarketScan research databases for life sciences researchers. NY: IBM Watson Health; 2021.
   Google Scholar
• Mcqueen R, Pnm AG, Juneja R, et al. Longitudinal relationship between time in range and HbA1c in a real‐world clinical practice setting. Adv Technol Treatments Diab; Barcelona: Diabetes Technology & Therapeutics; 2022. p. A-1. A-237.
   Google Scholar
• Perez-Nieves M, Hankosky ER, Fan L, et al. 75-LB: use of continuous glucose monitoring (CGM) and its association with economic outcomes in the real-world setting. Diabetes. 2022;71(Supplement_1):75-LB.
   Web of Science ®Google Scholar
• Agarwal S, Simmonds I, Myers AK. The use of diabetes technology to address inequity in health outcomes: limitations and opportunities. Curr Diab Rep. 2022;22(7):275–281.
   PubMed Web of Science ®Google Scholar